Fig. 5. Role of ERK1/2 in the hypnotic effect of β-Lap. Effect of MEK/ERK inhibitor on the changes in (A) sleep onset latency and (B) total sleep time. U0126 (10 mg/kg, i.p.) was injected to mice 30 min before administration of β-Lap (1 mg/kg, p.o.). Pentobarbital (45 mg/kg, i.p.) was injected 30 min after administration of β-Lap. Data are expressed as mean ± SEM (n=4-5). The changes in (C) p-ERK expression in the cortex of ICR mice. Western blot analysis of expression level of p-ERK was normalized against unphosphorylated form. β-Lap was administered, and 1 h later, the mice were sacrificed. DPCPX (5 mg/kg, p.o.) was administered 15 min before administration of β-Lap. Data are expressed as mean ± SEM (n=4). **p<0.01 vs CTL; #p<0.05 vs VEH; ##p<0.01 vs VEH. CTL, control; VEH, Vehicle; β-Lap, β-lapachone; DPCPX, 8-cyc lopentyl-1,3-dipropylxanthine; U0126, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene; p.o., Per oral; i.p., Intraperitoneal.
© Biomolecules & Therapeutics
